Azithromycin

Generic Name: Azithromycin

Brand Names: Azasite, Zithromax, Zmax

Drug Type: Small Molecule

Chemical Formula: C_₃₈H_₇₂N_₂O_₁₂

CAS Number: 83905-01-5

Unique Ingredient Identifier: J2KLZ20U1M

Background: Azithromycin is a broad-spectrum macrolide antibiotic with a long half-life and a high degree of tissue penetration . It was initially approved by the FDA in 1991 .
...

Indication: Azithromycin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria in order to prevent the development antimicrobial resistance and maintain the efficacy of azithromycin .
...

Associated Conditions: Acute Bacterial Sinusitis (ABS), Acute Otitis Media (AOM), Acute bacterial exacerbation of COPD caused by Haemophilus Influenza Infections, Moraxella Catarrhalis Infection, Streptococcus Pneumoniae Infections, Bacterial Conjunctivitis, Bacterial Sinusitis, Cervicitis, Chancroid, Community Acquired Pneumonia (CAP), Genital Ulcer Disease (GUD), Pelvic Inflammatory Disease (PID), Pharyngitis, Streptococcal Pharyngitis, Tonsillitis bacterial, Tonsillitis streptococcal, Traveler's Diarrhea, Uncomplicated Skin and Skin Structure Infections, Urethritis

Associated Therapies: -

Clinical Trials

Single Dose Azithromycin to Prevent Cholera in Children

Phase 2

Recruiting

Conditions: Cholera

Interventions: Drug: Azithromycin
Biological: Placebo

First Posted Date: 2020-03-30

Last Posted Date: 2022-05-31

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 920

Registration Number: NCT04326478

Locations: 🇧🇩
icddr,b Dhaka hospital, Dhaka, Bangladesh

Proactive Protection With Azithromycin and hydroxyChloroquine in Hospitalized Patients With COVID-19

Phase 2

Terminated

Conditions: Infection Viral
Virus Diseases
Corona Virus Infection

Interventions: Drug: Placebo oral tablet
Drug: Azithromycin
Drug: Hydroxychloroquine

First Posted Date: 2020-03-26

Last Posted Date: 2021-06-29

Lead Sponsor: Chronic Obstructive Pulmonary Disease Trial Network, Denmark

Target Recruit Count: 117

Registration Number: NCT04322396

Locations: 🇩🇰
Aalborg Sygehus, Aalborg, Denmark
🇩🇰
Herlev-Gentofte Hospital, Copenhagen, Denmark
🇩🇰
Odense Universitetshospital, Odense, Denmark

and more 5 locations

Anti-viral Effects of Azithromycin in Patients With Asthma and COPD

Phase 4

Conditions: Asthma; Eosinophilic
Lung Diseases, Obstructive
Lung Diseases
Asthma
Immune System Diseases
COPD
Exacerbation Copd
Bronchial Diseases

Interventions: Drug: Placebo oral tablet
Drug: Azithromycin

First Posted Date: 2020-03-24

Last Posted Date: 2021-07-26

Lead Sponsor: Bispebjerg Hospital

Target Recruit Count: 100

Registration Number: NCT04319705

Locations: 🇩🇰
University Hospital Bispebjerg and Frederiksberg, Copenhagen, Denmark

Gut and Azithromycin Mechanisms in Infants and Children II

Phase 4

Completed

Conditions: Malaria

Interventions: Drug: Placebo
Drug: Azithromycin

First Posted Date: 2020-03-19

Last Posted Date: 2023-06-29

Lead Sponsor: University of California, San Francisco

Target Recruit Count: 449

Registration Number: NCT04315272

Locations: 🇧🇫
Centre de Recherche en santé de nouna, Nouna, Boucle Du Mouhoun, Burkina Faso

Finding the Optimal Regimen for Mycobacterium Abscessus Treatment

Phase 2

Recruiting

Conditions: Pulmonary Disease Due to Mycobacteria (Diagnosis)

Interventions: Drug: Amikacin
Drug: Tigecycline
Drug: Imipenem
Drug: Cefoxitin
Drug: Linezolid
Drug: Azithromycin
Drug: co-trimoxazole
Drug: Clarithromycin
Drug: Clofazimine
Drug: Doxycycline
Drug: Moxifloxacin
Drug: Ethambutol
Drug: Bedaquiline
Drug: Rifabutin

First Posted Date: 2020-03-17

Last Posted Date: 2024-12-11

Lead Sponsor: The University of Queensland

Target Recruit Count: 300

Registration Number: NCT04310930

Locations: 🇦🇺
St George Hospital, Kogarah, New South Wales, Australia
🇦🇺
Austin Hospital, Heidelberg, Victoria, Australia
🇦🇺
Royal Melbourne Hospital, Parkville, Victoria, Australia

and more 47 locations